Minden BioPharmaceuticals

Minden Biopharma is a clinical-stage biotechnology company specializing in the discovery and development of next-generation biologics for oncology and immunological disorders. The company's core expertise lies in its proprietary bifunctional fusion protein platform, which enables the creation of molecules that simultaneously target multiple disease pathways, such as immune checkpoints and immunosuppressive cytokines. Its lead candidate, MDN-001, is a PD-L1/TGF-beta bifunctional fusion protein designed to restore anti-tumor immunity in patients with advanced solid tumors. MDN-001 is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and preliminary efficacy. Beyond its lead program, the company is advancing a pipeline of monoclonal and multispecific antibodies targeting Claudin 18.2 and other high-value oncology targets. With operations in Hong Kong and mainland China, Minden Biopharma is committed to delivering transformative therapies that address significant unmet needs in the global healthcare market.